BACKGROUND: The number of elderly patients suffering from ischemic stroke is rising. Randomized trials of mechanical thrombectomy (MT) generally exclude patients over the age of 80 years with baseline disability. The aim of this study was to understand the efficacy and safety of MT in elderly patients, many of whom may have baseline impairment. METHODS: Between January 2015 and April 2017, 96 patients ≥80 years old who underwent MT for stroke were selected for a chart review. The data included baseline characteristics, time to treatment, the rate of revascularization, procedural complications, mortality, and 90-day good outcome defined as a modified Rankin Scale (mRS) score of 0-2 or return to baseline. RESULTS: Of the 96 patients, 50 had mild baseline disability (mRS score 0-1) and 46 had moderate disability (mRS score 2-4). Recanalization was achieved in 84% of the patients, and the rate of symptomatic hemorrhage was 6%. At 90 days, 34% of the patients had a good outcome. There were no significant differences in good outcome between those with mild and those with moderate baseline disability (43 vs. 24%, p = 0.08), between those aged ≤85 and those aged > 85 years (40.8 vs. 26.1%, p = 0.19), and between those treated within and those treated beyond 8 h (39 vs. 20%, p = 0.1). The mortality rate was 38.5% at 90 days. The Alberta Stroke Program Early CT Score (ASPECTS) and the National Institutes of Health Stroke Scale (NIHSS) predicted good outcome regardless of baseline disability (p < 0.001 and p = 0.009, respectively). CONCLUSION: Advanced age, baseline disability, and delayed treatment are associated with sub-optimal outcomes after MT. However, redefining good outcome to include return to baseline functioning demonstrates that one-third of this patient population benefits from MT, suggesting the real-life utility of this treatment.
BACKGROUND: The number of elderly patients suffering from ischemic stroke is rising. Randomized trials of mechanical thrombectomy (MT) generally exclude patients over the age of 80 years with baseline disability. The aim of this study was to understand the efficacy and safety of MT in elderly patients, many of whom may have baseline impairment. METHODS: Between January 2015 and April 2017, 96 patients ≥80 years old who underwent MT for stroke were selected for a chart review. The data included baseline characteristics, time to treatment, the rate of revascularization, procedural complications, mortality, and 90-day good outcome defined as a modified Rankin Scale (mRS) score of 0-2 or return to baseline. RESULTS: Of the 96 patients, 50 had mild baseline disability (mRS score 0-1) and 46 had moderate disability (mRS score 2-4). Recanalization was achieved in 84% of the patients, and the rate of symptomatic hemorrhage was 6%. At 90 days, 34% of the patients had a good outcome. There were no significant differences in good outcome between those with mild and those with moderate baseline disability (43 vs. 24%, p = 0.08), between those aged ≤85 and those aged > 85 years (40.8 vs. 26.1%, p = 0.19), and between those treated within and those treated beyond 8 h (39 vs. 20%, p = 0.1). The mortality rate was 38.5% at 90 days. The Alberta Stroke Program Early CT Score (ASPECTS) and the National Institutes of Health Stroke Scale (NIHSS) predicted good outcome regardless of baseline disability (p < 0.001 and p = 0.009, respectively). CONCLUSION: Advanced age, baseline disability, and delayed treatment are associated with sub-optimal outcomes after MT. However, redefining good outcome to include return to baseline functioning demonstrates that one-third of this patient population benefits from MT, suggesting the real-life utility of this treatment.
Authors: Mònica Millán; Sebastià Remollo; Helena Quesada; Arturo Renú; Alejandro Tomasello; Priyanka Minhas; Natalia Pérez de la Ossa; Marta Rubiera; Laura Llull; Pedro Cardona; Fahad Al-Ajlan; María Hernández; Zarina Assis; Andrew M Demchuk; Tudor Jovin; Antoni Dávalos Journal: Stroke Date: 2017-03-14 Impact factor: 7.914
Authors: Gregg C Fonarow; Mathew J Reeves; Xin Zhao; DaiWai M Olson; Eric E Smith; Jeffrey L Saver; Lee H Schwamm Journal: Circulation Date: 2010-02-08 Impact factor: 29.690
Authors: Nils H Mueller-Kronast; Osama O Zaidat; Michael T Froehler; Reza Jahan; Mohammad Ali Aziz-Sultan; Richard P Klucznik; Jeffrey L Saver; Frank R Hellinger; Dileep R Yavagal; Tom L Yao; David S Liebeskind; Ashutosh P Jadhav; Rishi Gupta; Ameer E Hassan; Coleman O Martin; Hormozd Bozorgchami; Ritesh Kaushal; Raul G Nogueira; Ravi H Gandhi; Eric C Peterson; Shervin R Dashti; Curtis A Given; Brijesh P Mehta; Vivek Deshmukh; Sidney Starkman; Italo Linfante; Scott H McPherson; Peter Kvamme; Thomas J Grobelny; Muhammad S Hussain; Ike Thacker; Nirav Vora; Peng Roc Chen; Stephen J Monteith; Robert D Ecker; Clemens M Schirmer; Eric Sauvageau; Alex Abou-Chebl; Colin P Derdeyn; Lucian Maidan; Aamir Badruddin; Adnan H Siddiqui; Travis M Dumont; Abdulnasser Alhajeri; M Asif Taqi; Khaled Asi; Jeffrey Carpenter; Alan Boulos; Gaurav Jindal; Ajit S Puri; Rohan Chitale; Eric M Deshaies; David H Robinson; David F Kallmes; Blaise W Baxter; Mouhammad A Jumaa; Peter Sunenshine; Aniel Majjhoo; Joey D English; Shuichi Suzuki; Richard D Fessler; Josser E Delgado Almandoz; Jerry C Martin; Diogo C Haussen Journal: Stroke Date: 2017-08-22 Impact factor: 7.914
Authors: G Parrilla; E Carreón; J Zamarro; M Espinosa de Rueda; B García-Villalba; F Marín; F Hernández-Fernández; A Morales; M Fernández-Vivas; R Núñez; A Moreno Journal: Cardiovasc Intervent Radiol Date: 2014-06-13 Impact factor: 2.740
Authors: Mayank Goyal; Bijoy K Menon; Wim H van Zwam; Diederik W J Dippel; Peter J Mitchell; Andrew M Demchuk; Antoni Dávalos; Charles B L M Majoie; Aad van der Lugt; Maria A de Miquel; Geoffrey A Donnan; Yvo B W E M Roos; Alain Bonafe; Reza Jahan; Hans-Christoph Diener; Lucie A van den Berg; Elad I Levy; Olvert A Berkhemer; Vitor M Pereira; Jeremy Rempel; Mònica Millán; Stephen M Davis; Daniel Roy; John Thornton; Luis San Román; Marc Ribó; Debbie Beumer; Bruce Stouch; Scott Brown; Bruce C V Campbell; Robert J van Oostenbrugge; Jeffrey L Saver; Michael D Hill; Tudor G Jovin Journal: Lancet Date: 2016-02-18 Impact factor: 79.321
Authors: Sanjana Salwi; Shawna Cutting; Alan D Salgado; Kiersten Espaillat; Matthew R Fusco; Michael T Froehler; Rohan V Chitale; Howard Kirshner; Matthew Schrag; Adam Jasne; Tina Burton; Brian Mac Grory; Ali Saad; Mahesh V Jayaraman; Tracy E Madsen; Katarina Dakay; Ryan McTaggart; Shadi Yaghi; Pooja Khatri; Akshitkumar M Mistry; Eva A Mistry Journal: J Stroke Cerebrovasc Dis Date: 2020-06-05 Impact factor: 2.136
Authors: Hisham Salahuddin; Alicia C Castonguay; Syed F Zaidi; Richard Burgess; Ashutosh P Jadhav; Mouhammad A Jumaa Journal: Front Neurol Date: 2020-05-08 Impact factor: 4.003